RRRavi Reddy

Ravi Reddy

*This is an algorithmically generated author record based on publicly available information.

Ravi Reddy has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An In-vitro evaluation of a polyherbal formulation, against SARS-Cov-2

    by Divya Kanchibhotla, Saumya Subramanian, Reddy M. Ravi Kumar, K.R. Venkatesh Hari, Monika Pathania


  • Open Access

    Rate of Recovery and Symptomatic Efficacy of a Polyherbal AYUSH Formulation in the Treatment of SARS CoV-2 disease: A Single-arm trial

    by Divya Kanchibhotla, Prateek Harsora, Saumya Subramanian, Ravi Reddy, Hari Venkatesh

    Background The COVID-19 pandemic, caused by the human coronavirus SARS- CoV-2, has led to millions of deaths across the globe. Not only is the SARS-CoV-2 virus highly infectious, it also mutates very easily. This creates additional challenges for development of robust therapeutic solutions. Along with modern system of healthcare, there is a definite need for exploring natural plant based antiviral compounds directed against the SARS CoV-2 virus. Objective The present observational study investigates the efficacy of an Ayurvedic polyherbal formulation of 19 ingredients, NOQ19, in the management of COVID-19. Methodology: A single arm, single centric, open label study design was adopted for this feasibility study. 161 RT-PCR positive COVID-19 patients were enrolled. The enrolled participants were provided the Ayurvedic intervention, 2 tablets of NOQ19, thrice daily along with the standard of care treatment. Follow up COVID-19 RT- PCR tests were conducted on Day 5, Day 10 and Day 14, or until the patient turned negative. The time required for testing negative on the RT-PCR test or becoming asymptomatic was noted. Results A subjective analysis demonstrated that 74% of patients turned RT-PCR negative within 5 days of taking NOQ19. Additionally, 98% of the subjects turned RT-PCR Negative on Day 10 after taking NOQ19 in addition to the standard of care treatment of Vitamin C, Zinc and antipyretic (as necessary). None of the participants reported any adverse or side effects to the medication. Conclusion NOQ19 Ayurvedic polyherbal formulation can be an effective and safe option for the symptomatic management of COVID-19.

  • Open Access

    In vivo efficacy and safety of Siddha medicine Kabasura Kudineer among COVID 19 infected Syrian golden hamsters.

    by Kanchibhotla Divya, Jeetu Pathak, Ravi Kumar M Reddy, Venkatesh Hari K. R

    Background: The COVID-19 pandemic has overburdened current healthcare system and highlighted the need to explore potent remedies in Traditional medicine systems. Kabasura Kudineer (KSK), a poly herbal Siddha medicine, has shown great potential in treating COVID-19.Objective: The objective of the study is to explore the safety and efficacy of Kabasura Kudineer in a preclinical model for COVID-19: Syrian Golden Hamsters.Methods: This research study investigates the in vivo efficacy and safety of the well-known antiviral Siddha medicine KSK as a powdered tablet on COVID-19 infected Syrian golden hamsters. A total of 19 female hamsters were infected with the virus cell culture through intranasal route. 4 out of 19 animals were mock controls, 5 were infection controls, 4 were treated with remdesivir and acted as positive controls and remaining 6 were treated with KSK. The hamsters were observed for any adverse events, followed by their sacrifice on day 4 after inoculation with the virus. The lung pathology and viral load was studied for each hamster.Results: Therapeutic use of intraperitoneal instillation of Siddha formulation KSK reduces SARS-CoV-2 viral load and associated gross clinical parameters. Results showed significant reduction of 65% in the viral load for the KSK arm as compared to the infection control.Conclusion: We observed that the animals treated with KSK exhibited less severe pathology compared to the untreated infected group. No toxicity or adverse events were observed in the KSK group. This pre-clinical study supports the safety and efficacy of KSK.Study Registration: FNDR’s Institutional Animal Ethics Committee (IAEC), Registration Number 2082/PO/Rc/S/19/CPCSEA


  • Open Access

    In vitro evaluation of antiviral efficacy of a Siddha Formulation against SARS-CoV-2

    by Divya Kanchibhotla, Jeetu Pathak, Hari Venkatesh K.R., Ravi Reddy, Monika Pathania

    Introduction: SARS-CoV-2 virus caused COVID-19 pandemic with 218 million cases and 45 million deaths world over. It has challenged the already overburdened healthcare systems and created an urgent need to investigate solutions present in other healthcare systems. In this study Kabasura Kudineer is investigated as an intervention to influence the immune response which is beneficial for the host and stop the viral replication. Methods: Kabasura Kudineer is a polyherbal formulation containing 15 herbal drugs mixed in equal quantity. It is an official Siddha formulation, used for phlegmatic fevers and flu-like symptoms. To conduct this study Vero E6 (CL1008), the African monkey kidney epithelial cell line was taken and infected with SARS-CoV-2 viral isolate. The Kabasura Kudineer was added in different concentrations; 0.5 mg/mL, 0.25 mg/mL, 0.12 mg/mL, 0.06 mg/mL and 0.03 mg/mL to the infected cells respectively. These cell plates were incubated for 3 days in 5% CO2 incubator. Remdesivir was used as a positive control. The cells were fixed with formaldehyde, stained with crystal violet and plaques were visualised. Plaques were counted as PFU/ml. Result: Kabasura Kudineer was found to exhibit good antiviral activity against SARS-CoV-2. The highest antiviral activity was 81.5% at a concentration of 0.5 mg/ml. The IC-50 value was found to be 0.2 mg/mL. Conclusion: The antiviral efficacy of Kabasura Kudineer in our study showed reduction in the viral load which supports the results of clinical studies. Kabasura Kudineer can be used widely in a clinical setting as a treatment for COVID-19.

  • Open Access

    To study the in-vivo efficacy and safety of AYUSH polyherbal formulation among COVID-19 infected Syrian gold hamsters

    by Divya Kanchibhotla, Saumya Subramanian, Hari Venkatesh K.R., Ravi Reddy

    The COVID-19 pandemic has infected millions of people around the world and the resulting disease burden has challenged the already stressed healthcare systems globally. Amidst the increasing morbidity rate of SARS-CoV-2, the scientific community is vigorously researching possible remedies targeted against the virus. Natural herbs have a great potency to cure infectious diseases and are vastly unexplored. The present study aims to investigate Ayurvedic herbs in a unique polyherbal formulation, NOQ19, against the SARS-CoV-2 virus in an animal model. A total of 19 female Syrian hamsters were infected with the virus cell culture through intranasal route. 4 out of 19 animals were mock controls, 5 were infection controls, 4 were treated with remdesivir and acted as positive controls and remaining 6 were treated with NOQ19. The hamsters were observed to note body weight reduction and adverse events followed by sacrifice on day 4 after inoculation with the virus. The lung pathology and viral load was studied in each hamster. Results showed a significant reduction of 78.2% in the viral load for the NOQ19 arm, as compared to the infection control. Gross examination of the lung histology of the NOQ19 arm suggested an improvement in edema and congestion compared to the infection control. Also, no adverse events were noticed in NOQ19 hamster group. Therefore, the authors propose NOQ19 formulation as a potential option to be tested further for its efficacy and efficiency against COVID-19.

  • Open Access

    An In-vitro evaluation of a polyherbal formulation, against SARS-CoV-2

    by Divya Kanchibhotla, Saumya Subramanian, Ravi Reddy, Hari Venkatesh K.R., Monika Pathania

    Background: COVID-19, caused by SARS-CoV-2 is one of the major health crisis that has affected the world in the past century. With the emergence of new strains of viruses and antimicrobial resistance, the world is looking for an alternate therapeutic option to fight infectious disease.Objective: The present study evaluated the efficacy of a novel polyherbal formulation, named NOQ19, against SARS-CoV-2 in an in vitro setting. NOQ 19 is an unique blend of 13 Ayurvedic herbs.Methodology: Vero E6 (CL1008), the African green monkey kidney epithelial cell, were infected with SARS-CoV-2 virus (isolate USA-WA1/2020) in a 96 well-plate. NOQ19 test material was diluted in different concentration as follows 0.05mg/ml, 0.1mg/ml, 0.2mg/ml, 0.3mg/ml, 0.4mg/ml, 0.5mg/ml, 0.6mg/ml, 0.7mg/ml, 0.8mg/ml and 0.9mg/ml. These different concentrations of NOQ19 were added to infected cells respectively and incubated for 3 days in 5% CO2 incubator. Remdesivir was used as a positive control.The cells were finally fixed with formaldehyde, stained with crystal violet and plaques were visualized. The number of plaques were counted to determine the PFU(plaque forming units)/mL.Results: Results demonstrated 100% antiviral efficacy of NOQ19 at 0.9mg/ml concentration with complete elimination of the virus. The IC50 of the drug was found to be 0.2mg/ml. The results of the present study demonstrated viral load reduction in SARS- CoV-2 infected Vero E6 cell lines.Conclusion: The result along with clinical trials could propose NOQ19 as a potential therapeutic option in the fighting the COVID-19 challenge.